Go Pro
LON:SN

Smith & Nephew (SN) Share Price, News & Analysis

Smith & Nephew logo
GBX 982.40 -14.78 (-1.48%)
As of 10/1/2026

About Smith & Nephew Stock (LON:SN)

Advanced

Key Stats

Today's Range
980.40
▼
1,009.10
50-Day Range
1,004.50
▼
1,214.50
52-Week Range
N/A
Volume
2.00 million shs
Average Volume
343,671 shs
Market Capitalization
£10.77 billion
P/E Ratio
35.37
Dividend Yield
3.66%
Price Target
GBX 1,293.33
Consensus Rating
Hold

Company Overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

SN MarketRank™: 

Smith & Nephew scored higher than 76% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Smith & Nephew has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 6 hold ratings, and no sell ratings.

  • Upside Potential

    Smith & Nephew has a consensus price target of GBX 1,293.33, representing about 31.7% upside from its current price of GBX 982.40.

  • Amount of Analyst Coverage

    Smith & Nephew has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Smith & Nephew's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Smith & Nephew is 35.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.90.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Smith & Nephew is 35.37, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.61.

  • Price to Earnings Growth Ratio

    Smith & Nephew has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Smith & Nephew has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SN.
  • Dividend Leadership

    Smith & Nephew is a leading dividend payer. It pays a dividend yield of 3.66%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Smith & Nephew does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Smith & Nephew is 104.41%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Smith & Nephew's dividend.
  • Search Interest

    Only 32 people have searched for SN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Smith & Nephew insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.19% of the stock of Smith & Nephew is held by insiders.

  • Percentage Held by Institutions

    62.24% of the stock of Smith & Nephew is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Smith & Nephew's insider trading history.
Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SN Stock News Headlines

Berenberg Bank Reaffirms Their Hold Rating on Smith & Nephew (SN)
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel
Smith & Nephew (SN) Gets a Hold from UBS
Smith+Nephew CFO John Rogers to Leave for U.S. Role
Barclays downgrades Smith & Nephew (SN) to a Sell
See More Headlines

SN Stock Analysis - Frequently Asked Questions

Smith & Nephew's stock was trading at GBX 1,238.50 at the beginning of the year. Since then, SN shares have decreased by 20.7% and is now trading at GBX 982.40.

Shares of SN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew SNATS (SNN), Barclays (BARC), Lloyds Banking Group (LLOY), GSK (GSK), AstraZeneca (AZN) and Meta Platforms (META).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Healthcare Equipment & Supplies
Sub-Industry
N/A
Current Symbol
LON:SN
CIK
N/A
Fax
N/A
Employees
18,452
Year Founded
N/A

Price Target and Rating

High Price Target
GBX 1,600
Low Price Target
GBX 1,000
Potential Upside/Downside
+31.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
GBX 27.77
Trailing P/E Ratio
35.37
Forward P/E Ratio
10.58
P/E Growth
0.46
Net Income
£382.79 million
Net Margins
10.08%
Pretax Margin
N/A
Return on Equity
12.25%
Return on Assets
4.51%

Debt

Debt-to-Equity Ratio
73.07
Current Ratio
2.14
Quick Ratio
0.84

Sales & Book Value

Annual Sales
£7.08 billion
Price / Sales
1.52
Cash Flow
GBX 52.58 per share
Price / Cash Flow
18.68
Book Value
GBX 595.90 per share
Price / Book
1.65

Miscellaneous

Outstanding Shares
1,096,260,062
Free Float
N/A
Market Cap
£10.77 billion
Optionable
Not Optionable
Beta
0.69
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (LON:SN) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners